Despite Genotyping Growth, Affymetrix's Q3 Sales Fall 5 Percent on Service Slowdown
November 02, 2010
Despite Genotyping Growth, Affymetrix's Q3 Sales Fall 5 Percent on Service Slowdown
While Affy officials said they were "surprised" by the decrease in service revenues, they cited "steady progress" in the company's genotyping and expression businesses.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Affy Posts 6 Percent Decrease in Q2 Sales as it Prepares to Launch Next-Gen Genotyping Offering
July 28, 2009 / BioArray News - Affymetrix Sees 'Opportunity' for Diagnostics Business in Increased FDA Oversight of LDTs
September 21, 2010 / BioArray News - Affy Files CytoScan with FDA, Plans 'Aggressive' Marketing Campaign to Grow Cyto Business
February 19, 2013 / BioArray News - After 'Pivotal' 2012, Affy Looks to CytoScan, Axiom Genotyping Products to Drive Future Growth
February 5, 2013 / BioArray News - Illumina Predicts Flat Future for Array Business as GWAS Decline Counters Growth in New Markets
October 30, 2012 / BioArray News